---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Access and distribution"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Access and distribution. Topics: Commercial availability and treatment site coordination, Transition from the Expanded Access Program to commercial treatment, Distribution: exclusive specialty distributor, Medical buy-and-bill and billing codes, and 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/access-and-distribution"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Commercial availability and treatment site coordination

> “Finding an appropriate treatment site is critical for families.”
> “A dedicated Beren Family Access Manager (FAM) will serve as a single point of contact, working directly with families to help identify an appropriate site of care, ideally close to home, and coordinate access to treatment.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.1.2.11-2"></a>

### Transition from the Expanded Access Program to commercial treatment

> “If your child is in the Expanded Access Program, a Beren Family Access Manager can begin helping you plan the transition to commercial treatment immediately, even before LEMBAZ is available at those sites.”

Source: [Beren Therapeutics LEMBAZ approval community update (2026)](https://www.berentx.com/news/community-update-lembaz-adrabetadex-is-approved/)

<a id="topic-2.1.2.11-3"></a>

### Distribution: exclusive specialty distributor

> “Lembaz is exclusively available through CuraScript SD by Evernorth”
> “Contact CuraScript SD by Evernorth to begin ordering Lembaz”

Source: [LEMBAZ prior authorization checklist (2026)](https://lembazrx.com/wp-content/uploads/prior-authorization-checklist.pdf)

<a id="topic-2.1.2.11-4"></a>

### Medical buy-and-bill and billing codes

> “This brochure is designed to support your practice or site of care with accurate and efficient claim preparation for Lembaz in medical buy-and-bill settings.”
> “At this time, Lembaz does not have a product-specific HCPCS code.”
> “C9399, J3490, and J3590 are not interchangeable.”

Source: [LEMBAZ billing and coding guide (2026)](https://lembazrx.com/wp-content/uploads/billing-coding-guide.pdf)

| Code | Description |
| --- | --- |
| HCPCS C9399 | “Unclassified drugs or biologics. Hospital outpatient/OPPS-oriented use; payer and facility validation required.” |
| HCPCS J3490 | “Unclassified drugs. Professional/CMS-1500 or payer-directed miscellaneous drug pathway.” |
| ICD-10-CM E75.242 | “Niemann-Pick disease, type C” |
| CPT 62329 | “Injection of diagnostic or therapeutic substance into the subarachnoid (intrathecal) space, including needle placement and imaging guidance (fluoroscopy or CT).” |
| CPT 00635 | “Anesthesia for procedures in lumbar region (diagnostic or therapeutic lumbar puncture)” |

Source: [LEMBAZ billing and coding guide (2026)](https://lembazrx.com/wp-content/uploads/billing-coding-guide.pdf)

<a id="topic-2.1.2.11-5"></a>

### Prior authorization documentation

> “Confirm the patient’s benefits and the health plan’s requirements for the prior authorization (PA), treatment location, coding, billing, and patient costs”
> “Relevant clinical documentation, including a complete baseline audiology evaluation before treatment”
> “Documentation of prior Expanded Access Program (EAP) participation, if applicable”
> “Confirm that the request lists the planned dose, number of vials or billing units, dosing frequency, NDC, and any procedure or HCPCS codes required by the plan”

Source: [LEMBAZ prior authorization checklist (2026)](https://lembazrx.com/wp-content/uploads/prior-authorization-checklist.pdf)

> “The following document includes possible content to be used as a letter of medical necessity in support of a patient receiving Lembaz™ (adrabetadex) for the treatment of Niemann-Pick disease, type C, with neurological manifestations that started at less than 6 years of age.”

Source: [LEMBAZ letter of medical necessity template (2026)](https://lembazrx.com/wp-content/uploads/medical-necessity-template.pdf)

<a id="topic-2.1.2.11-6"></a>

### Enrollment form

> “For Specialty Pharmacy prescriptions, I authorize Lembaz™ Family Support to transmit the above prescription to the appropriate Specialty Pharmacy for my patient.”
> “Has an Audiology Test Been Completed?”

Source: [LEMBAZ patient enrollment form (2026)](https://lembazrx.com/wp-content/uploads/patient-enrollment-form.pdf)

<a id="topic-2.1.2.11-7"></a>

### Patient support program: LEMBAZ Family Support

> “The LEMBAZ Family Support program offers comprehensive financial assistance and personalized support through a dedicated Beren team that provides one-on-one help navigating the treatment journey.”
> “Out-of-pocket assistance: full out-of-pocket assistance for eligible families, so that there is no out-of-pocket cost to families”
> “Insurance & logistics navigation: dedicated Beren case managers help coordinate insurance coverage, travel logistics and other practical aspects of treatment to enable patients to start and stay on therapy”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

> “If you have commercial or private insurance, you may be able to pay $0 for Lembaz and services associated with your treatment.”
> “Eligible families may qualify for help with Lembaz costs through the Patient Assistance Program (PAP).”
> “Bridge support may be available to help your loved one get started while coverage is being worked out.”

Source: [LEMBAZ caregiver website (2026)](https://lembazrx.com/)

<a id="topic-2.1.2.11-8"></a>

### Out-of-pocket, bridge, and patient assistance program terms

> “The Program is not valid for patients enrolled in any state or federal government program, including, but not limited to, Medicaid/Managed Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico government insurance, or any state pharmaceutical assistance program.”
> “Not eligible for the Program if rare disease is a benefit exclusion or carve out.”
> “This Program may not be redeemed for more than the approved dose, max of 26 doses per year, given as an IT every 2 weeks.”
> “The Program is valid for 2 years and requires re-enrollment in the 21st month of the Program.”
> “If you may be eligible for Medicaid, you will be required to provide documentation of a Medicaid final denial before being evaluated for PAP eligibility.”

Source: [LEMBAZ Family Support terms and conditions (2026)](https://lembazrx.com/Co-Pay)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
